WS
MRTX

Wedbush Securities’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Wedbush Securities’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,100
Closed -$57K – 893
2016
Q4 		$57K Buy
+12,100
New +$65.8K 0.01% 772

Other funds holding MRTX

AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wedbush Securities's MRTX Position: Q1 2017 in Review

Wedbush Securities sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2017, closing a stake of 12,100 shares — an estimated $57K sold.

Wedbush Securities first reported a position in MRTX in Q4 2016 and held it in 1 quarter. The position peaked at $57K in Q4 2016. 64 funds tracked by Wall St. Rank hold MRTX as of Q1 2017.

  • Wedbush Securities reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Wedbush Securities sold 12,100 Mirati Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $57K.
  • Wedbush Securities first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Wedbush Securities's Mirati Therapeutics, Inc. Common Stock position peaked at $57K in Q4 2016.
  • 64 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Wedbush Securities's 13F filing for Q1 2017, filed 5 May 2017.